Therapeutic Advances in Thrombosis

Managing patients with thrombotic vascular disease is complex and challenging:

Ischemic vascular disease remains a complicated interplay of atherosclerosis and thrombosis - even with the evolution in our understanding of the pathobiology of thrombosis.
There has been tremendous growth in therapeutic options which are quickly finding their place in daily practice, including a remarkable expansion in the number of intravenous and oral antithrombotic agents and new antiplatelet agents
Now more than ever, all cardiologists, hematologists, and specialists in vascular medicine, as well as other professionals, such as hospital pharmacists, who deal with prognosis and intervention in preventing thrombosis, need a resource that distills current knowledge of this important subject.

Written and edited by today's leading international, Therapeutic Advances in Thrombosis, 2e provides physicians with the very latest in medical and surgical advances in antithrombotic therapies. With this comprehensively updated edition you get:

Coverage of virtually all aspects of venous and arterial thrombotic disease and the corresponding therapies
Strategies to manage specific clinical conditions and how to tailor treatment to individual patient needs
Updated chapters covering thrombolysis in ST-elevated myocardial infarctions; thrombosis in patients with diabetes, pregnancy, and renal dysfunction
Special emphasis on the pharmacology of novel anticoagulants and their practical use in venous thromboembolism and atrial fibrillation.
Plus, all chapters fully explore clinical trial designs and outcomes for particular treatment therapies, as well as contain the relevant ACC/AHA/ESC guidelines, so you can confidently apply what you learn.

Résumé
Managing patients with thrombotic vascular disease is complex and challenging:Ischemic vascular disease remains a complicated interplay of atherosclerosis and thrombosis—even with the evolution in our understanding of the pathobiology of thrombosis.There has been tremendous growth in therapeutic options which are quickly finding their place in daily practice, including a remarkable expansion in the number of intravenous and oral antithrombotic agents and new antiplatelet agentsNow more than ever, all cardiologists, hematologists, and specialists in vascular medicine, as well as other professionals, such as hospital pharmacists, who deal with prognosis and intervention in preventing thrombosis, need a resource that distills current knowledge of this important subject.Written and edited by today’s leading international, Therapeutic Advances in Thrombosis, 2e provides physicians with the very latest in medical and surgical advances in antithrombotic therapies. With this comprehensively updated edition you get:Coverage of virtually all aspects of venous and arterial thrombotic disease and the corresponding therapiesStrategies to manage specific clinical conditions and how to tailor treatment to individual patient needsUpdated chapters covering thrombolysis in ST-elevated myocardial infarctions; thrombosis in patients with diabetes, pregnancy, and renal dysfunctionSpecial emphasis on the pharmacology of novel anticoagulants and their practical use in venous thromboembolism and atrial fibrillation.Plus, all chapters fully explore clinical trial designs and outcomes for particular treatment therapies, as well as contain the relevant ACC/AHA/ESC guidelines, so you can confidently apply what you learn.

Contenu

Contributors, vii

Foreword, x

Preface, xi

1 Arterial thrombosis: a brief overview, 1
Lina Badimon and Valentin Fuster

2 Aspirin, 12
*Carlo Patrono
*

3 Platelet ADP P2Y12 inhibitors: thienopyridines, 26
Joseph D. Foley III and David J. Moliterno

4 Platelet ADP P2Y12 inhibitors: nonthienopyridines, 47
Joseph D. Foley III and David J. Moliterno

5 Cilostazol and dipyridamole: more than weak inhibition of platelets, 62
Wolfgang G. Eisert

6 Interrelationship of thrombin and platelets: the protease activated receptor-1, 71
Matthew E. Wiisanen and David J. Moliterno

7 Glycoprotein IIb/IIIa inhibitors, 87
Marco Valgimigli and Elisa Cangiano

8 Unfractionated heparin and low molecular weight heparin in ischemic heart disease, 111
Zafar Iqbal, Omar Hasan, and Marc Cohen

9 Pentasaccharide derivatives, 128
Antonio Gutierrez, Pierluigi Tricoci, and John H.P. Alexander

10 Intravenous direct thrombin inhibitors, 150
Femi Philip and A. Michael Lincoff

11 Vitamin K antagonists, 166
Freek W.A. Verheugt

12 Oral direct thrombin inhibitors and oral factor Xa inhibitors, 180
Steen Husted and Lars Wallentin

13 Thrombolytic therapy and concomitant antithrombotic therapies, 189
Peter R. Sinnaeve and Frans J. Van de Werf

14 Antithrombotic therapy in ST-segment elevation myocardial infarction, 205
Kurt Huber, Raffaele De Caterina, and Steen Dalby Kristensen

15 Antithrombotic therapy in non–ST-segment elevation acute coronary syndromes, 213
Georgios J. Vlachojannis, Vijayalakshmi Kunadian, Joseph M. Sweeny, and Roxana Mehran

16 Antithrombotic strategies in patients undergoing elective percutaneous coronary intervention, 236
Sunil V. Rao and E. Magnus Ohman

17 Antithrombotic management in patients with prosthetic valves, 246
Eric G. Butchart and Raffaele De Caterina

18 Stroke: thrombolysis and antithrombotic therapy, 272
L. Creed Pettigrew and Michael R. Dobbs

19 Atrial fibrillation: current and forthcoming antithrombotic therapies, 285
Raffaele De Caterina and Giulia Renda

20 Venous thromboembolism: pathophysiology, diagnosis, and prophylaxis, 306
Marco P. Donadini, Walter Ageno, and Alexander G. Turpie

21 Antithrombotic therapy in venous thrombosis and pulmonary embolism, 317
Marcello Di Nisio and Harry R. Büller

22 Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, hypercoagulable states, pregnancy, and renal insufficiency, 327
Meyer Michel Samama, Jacqueline Conard, and Grigoris Gerotziafas

23 Genetics of the response to antithrombotic drugs and the need for monitoring, 357
Jean-Philippe Collet, Gilles Montalescot, and Jean-Sébastien Hulot

Index, 378